Received by email:

File: Stock Option Grant 25Nov15.docx

Sirona Biochem Grants Stock Options
Vancouver, British Columbia - November 25, 2015 - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) announces that it has g
--->ranted incentive stock options under its Stock Option Plan to directors and officers of the Company for the purchase o
--->f up to 1,200,000 common shares at a price of $0.19 per share for a period of two years.
About Sirona Biochem Corp.
 
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona spec
--->ializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patent
--->ed for maximum revenue potential. 

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and
---> ongoing royalty payments. Sirona's laboratory, TFChem, is located in France and is the recipient of multiple French n
--->ational scientific awards and European Union and French government grants. For more information visit www.sironabioche
--->m.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Vent
--->ure Exchange) accepts responsibility for the adequacy or accuracy of this release. 

For more information regarding this press release, please contact:

Christopher Hopton, CFO Sirona Biochem Corp.  Phone:  1.604.282.6064 Email: chopton@sironabiochem.com

---------------------------------------------
Sirona Biochem cautions you that statements included in this press release that are not a description of historical fa
--->cts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations
---> and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward
--->-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated 
--->otherwise.  Actual results, performance or achievement could differ materially from those expressed in, or implied by,
---> Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business 
--->including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delay
--->s in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse sid
--->e effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commer
--->cialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or bi
--->otechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does n
--->ot assume any obligation to update any forward-looking statements except as required by law.